Short answer
VERACYTE, INC. (VCYT) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Veracyte announced quarterly financial results for the period ended June 30, 2026.
VERACYTE, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Veracyte announced quarterly financial results for the period ended June 30, 2026
- Full results and investor-relevant metrics are provided in Exhibit 99.1
- Press release furnished under Item 2.02, not deemed filed under Exchange Act Section 18
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $150.3M, up 15%, with testing revenue $145.7M, up 19%, led by Decipher up 20% and Afirma up 18%
- GAAP net income $25.5M, or 17.0% of revenue, versus a $0.98M loss in Q2 2025
- Adjusted EBITDA $44.0M, margin 29.2%, up from 27.5%, signaling operating leverage despite 16% non-GAAP operating-expense growth
- 2026 revenue guidance raised to $590M-$596M, or 14%-15% growth, while testing revenue guidance increased to $576M-$582M
- Prosigna LDT and TrueMRD for MIBC launched, with Medicare coverage secured for TrueMRD, improving commercialization and reimbursement prospects
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other VERACYTE, INC. 8-K filings
Get the next VCYT 8-K as it lands
Follow VCYT for push alerts, or ask the research agent what this filing means.